Two new studies of the potential neuroprotective agent nerinetide for patients with acute ischemic stroke have shown conflicting results, with suggestions of benefit when given very early in the prehospital setting.
The large OPT-BIRISK trial adds important information to the complex puzzle of antithrombotic therapy after PCI for acute coronary syndrome, says one expert.
The findings support extended anticoagulation in patients with active, ongoing cancer and isolated distal DVT, with caveats, including the need for individualized patient treatment decisions.
He should be well served by lessons from last year s turbulent case of David Bennett, the first patient at the University of Maryland to receive a genetically modified porcine heart.